A-Z Indication Information.


83 Indication founds starts with "F"

Follicular lymphoma Fibromyalgia
Fat malabsortion Fatigue
Fever Fever & pain
Fibrocystic breast disease Flatulance
For growing children Functional disturbances
Fugl infec of oral cav/new bor Fungal infections of ear
For spinl anaethe of extd durn Filtering operatn for glaucoma
For posterior synecheia For tired & inflammed eyes
Favus Fissures
Fissures & infect of nipple Flexura prurigo
Folliculitis For rectal & vaginal lubricatn
For scalp and hairy skin inf Freckles
Fungal & gram+ve bact infectn Fungal infect ass dermatoses
Fungal infection of skin/nails Fungal infections of skin
Fungal infections Fungal infectn of mucocut junc
Fungal inflam wi infectn Fungal infstation of extnl ear
Fungal nappy rash Fungal/eczematised infectn
Fungl infect wi eczemt feature Fungl/bactl mxd skin infectn
Fungl& grm +ve bac inf skn/nls Furunculosis
Factor IX def(Christmas disea) Filariasis
Fibrositis Fracture/dislocation pain
Frozen shoulder Failure of nidation
Female infertility Frequency
Fatty infiltration of liver Fermentative dyspepsia
Food allergies Food poisoning
Functional G.I. disorders Functional diarrhoea
Functional dyspepsia Functional venous disorders
Fear Flatulent dyspepsia
Folic acid deficiency states Fungal infections of the eye
Free radical mediated disordr Falciparum malaria
For palliative treatment of Hodgkins disease For infiltration and nerve block
Facial fat loss ( lipoatrophy) Fabry Disease
Fibrinogen Deficiency For use in combination with Chlorambucil to treat patients with untreated lymphocytic leukemia (CLL)
For chronic weight management For use an adjunct (add-on) treatment for seizures associated with Lennox-Gastaut syndrome in adults and children 2 years of age and older
For use in patients undergoing magnetic resonance imaging (MRI) of the central nervous system For the Treatment of Postmenopausal Women with an Estrogen Receptor(ER)-Positive, Human Epidermal growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer as Initial Endocrine-based Therapy for Their Metastatic Disease
For the treatment of Patients with locally Recurrent or Metastatic, Progressive, Radioactive Iodine- Refractory Differentiated Thyroid Cancer For the treatment of Patients with Multiple Myeloma(MM), who have received at least 2 Prior Regimens,including Bortezomib and an Immunomodulatory Agent
For Complicated Urinary Tract Infections(CUTI) including Pyelonephritis and Complicated Intra-Abdominal Infections(CIAI) For Improvement in the Appearance of Moderate to Severe Convexity or Fullness Associated with Submetal Fat in Adults
For the treatment of Moderate to Severe Plaque Psoriasis in Adult Patients who are Candidates for Systemic Therapy or Phototherapy For the treatment of Pediatric Patients with High-Risk Neuroblastoma who Acheive at least a Partial Response to Prior First-Line Multiagent Multimodality Therapy
For the treatment of Patients with Locally Advanced Basal Cell Carcinoma(BCC) that has occurred following surgery or radiation therapy, or those who are not candidates for Surgery or Radiation Therapy For the treatment of Patients with metastatic Non-Small Cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutation as detected by an FDA -approved test
For use in combination with FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed on a first line Besvacizumab -,Oxaliplatin and Fluropyrimidine -containing regimen. For the treatment of Philadelphia Chromosome-Negative relapsed or Refractory B-cell precusor acute Lymphpblastic Leukemia(R/R ALL)
For the treatment of patients with unresectable or metastatic melanoma and disease progression following Ipilmimab and if BRAF V600 mutation positive a BRAF Inhibitor For the treatment of Persistent, Recurrent or Metastatic cervical cancer, in combination with Placitaxel and Cisplatin or Placitaxel and Topecan
For acute painful condition in adults